He did not tell his mainstream cancer doctors that he was also taking, among other things, the repurposed generic drug ivermectin.
Two years before Covid, researchers analyzed published data that strongly suggested ivermectin could be repurposed, namely put to another off-label use, for cancer.
In about twenty laboratory studies, ivermectin was found to inhibit cell proliferation and induce "Apoptosis"-cell death-in cancer cell lines of the breast, prostate, ovary, head and neck, colon, and pancreas.
"The in vitro and in vivo antitumor activities of ivermectin are achieved at concentrations that can be clinically reachable based on the human pharmacokinetic studies," stated the 2018 article in the American Journal of Cancer Research.
Dr. Kathleen Ruddy is a retired cancer surgeon who trained at Memorial Sloan-Kettering and cared for 10,000 breast cancer patients over a thirty-year career.
"They act on tumor stem cells and the tumor microenvironment. Unlike chemo, which only targets rapidly dividing cells, both ivermectin and mebendazole have been proven to act on multiple tumor pathways involving multiple different cancer types."
Fenbendazole has shown effectiveness in three human cancer cases and in laboratory experiments on ovarian and colon cancer cells.
No comments:
Post a Comment